At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 285 enrolled
Drug / intervention
5mg Serlopitant Tablets +1 moredrug
Likely dose
5mg Serlopitant Tabletsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis
In Brief
A Phase 3 clinical trial evaluating 5mg Serlopitant Tablets and Placebo Tablets for Pruritus and Prurigo Nodularis. Completed, enrolled 285 participants across 49 sites.
Detailed Summary
Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPruritus, Prurigo Nodularis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartMay 2018
First PostedJun 2018
Primary CompletionJan 2020
Study CompletionFeb 2020
TodayJul 2026
First PostedJun 6, 2018
Enrollment StartMay 2, 2018
Primary CompletionJan 14, 2020
Study CompletionFeb 14, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.1 years ago
Interventions
5mg Serlopitant Tabletsdrug
Serlopitant Tablets
Placebo Tabletsdrug
Placebo Tablets